Mutual of America Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.92M | Buy |
9,690
+738
| +8% | +$223K | 0.03% | 650 |
|
|
2026
Q1 | $2.96M | Sell |
8,952
-6,514
| -42% | -$2.22M | 0.03% | 596 |
|
|
2025
Q4 | $6.15M | Buy |
15,466
+159
| +1% | +$70.4K | 0.06% | 353 |
|
|
2025
Q3 | $6.98M | Sell |
15,307
-639
| -4% | -$260K | 0.07% | 304 |
|
|
2025
Q2 | $5.2M | Buy |
15,946
+2,302
| +17% | +$637K | 0.06% | 425 |
|
|
2025
Q1 | $3.68M | Buy |
13,644
+11,881
| +674% | +$3.05M | 0.04% | 561 |
|
|
2024
Q4 | $415K | Sell |
1,763
-161
| -8% | -$42.3K | ﹤0.01% | 1180 |
|
|
2024
Q3 | $529K | Buy |
1,924
+405
| +27% | +$105K | 0.01% | 1127 |
|
|
2024
Q2 | $369K | Hold |
1,519
| – | – | ﹤0.01% | 1220 |
|
|
2024
Q1 | $227K | Hold |
1,519
| – | – | ﹤0.01% | 1385 |
|
|
2023
Q4 | $291K | Sell |
1,519
-168
| -10% | -$28.6K | ﹤0.01% | 1305 |
|
|
2023
Q3 | $299K | Hold |
1,687
| – | – | ﹤0.01% | 1255 |
|
|
2023
Q2 | $320K | Buy |
1,687
+54
| +3% | +$10.7K | ﹤0.01% | 1267 |
|
|
2023
Q1 | $327K | Hold |
1,633
| – | – | ﹤0.01% | 1244 |
|
|
2022
Q4 | $388K | Sell |
1,633
-77
| -5% | -$16.4K | ﹤0.01% | 1186 |
|
|
2022
Q3 | $342K | Buy |
+1,710
| New | +$326K | ﹤0.01% | 1194 |
|
|
2021
Q2 | – | Sell |
-1,863
| Closed | -$263K | – | 1669 |
|
|
2021
Q1 | $263K | Sell |
1,863
-57
| -3% | -$8.58K | ﹤0.01% | 1284 |
|
|
2020
Q4 | $250K | Sell |
1,920
-108
| -5% | -$14.4K | ﹤0.01% | 1243 |
|
|
2020
Q3 | $295K | Hold |
2,028
| – | – | ﹤0.01% | 1147 |
|
|
2020
Q2 | $300K | Buy |
2,028
+525
| +35% | +$70.8K | ﹤0.01% | 1130 |
|
|
2020
Q1 | $164K | Hold |
1,503
| – | – | ﹤0.01% | 1145 |
|
|
2019
Q4 | $173K | Sell |
1,503
-229
| -13% | -$22.8K | ﹤0.01% | 1151 |
|
|
2019
Q3 | $139K | Hold |
1,732
| – | – | ﹤0.01% | 1155 |
|
|
2019
Q2 | $126K | Hold |
1,732
| – | – | ﹤0.01% | 1169 |
|
|
2019
Q1 | $162K | Sell |
1,732
-203
| -10% | -$17K | ﹤0.01% | 1145 |
|
|
2018
Q4 | $141K | Hold |
1,935
| – | – | ﹤0.01% | 1149 |
|
|
2018
Q3 | $169K | Hold |
1,935
| – | – | ﹤0.01% | 1161 |
|
|
2018
Q2 | $191K | Buy |
1,935
+960
| +98% | +$95.2K | ﹤0.01% | 1160 |
|
|
2018
Q1 | $116K | Buy |
+975
| New | +$126K | ﹤0.01% | 1147 |
|
|
2016
Q4 | – | Sell |
-17,092
| Closed | -$1.16M | – | 1210 |
|
|
2016
Q3 | $1.16M | Hold |
17,092
| – | – | 0.02% | 979 |
|
|
2016
Q2 | $948K | Buy |
17,092
+1,255
| +8% | +$79.1K | 0.02% | 1021 |
|
|
2016
Q1 | $994K | Sell |
15,837
-5,800
| -27% | -$386K | 0.02% | 1003 |
|
|
2015
Q4 | $2.04M | Buy |
21,637
+87
| +0.4% | +$8.07K | 0.05% | 658 |
|
|
2015
Q3 | $1.73M | Hold |
21,550
| – | – | 0.04% | 727 |
|
|
2015
Q2 | $2.58M | Sell |
21,550
-1,725
| -7% | -$206K | 0.06% | 568 |
|
|
2015
Q1 | $2.43M | Sell |
23,275
-664
| -3% | -$67.3K | 0.05% | 620 |
|
|
2014
Q4 | $2.32M | Sell |
23,939
-17,853
| -43% | -$1.65M | 0.05% | 627 |
|
|
2014
Q3 | $3.26M | Hold |
41,792
| – | – | 0.08% | 386 |
|
|
2014
Q2 | $2.64M | Sell |
41,792
-2,530
| -6% | -$150K | 0.06% | 530 |
|
|
2014
Q1 | $2.98M | Sell |
44,322
-9,000
| -17% | -$697K | 0.07% | 453 |
|
|
2013
Q4 | $3.43M | Sell |
53,322
-6,017
| -10% | -$359K | 0.08% | 365 |
|
|
2013
Q3 | $3.8M | Sell |
59,339
-42,705
| -42% | -$2.13M | 0.1% | 250 |
|
|
2013
Q2 | $3.16M | Buy |
+102,044
| New | +$2.72M | 0.09% | 291 |
|
Other funds holding ALNY
Mutual of America Capital Management's ALNY Position: Q2 2026 in Review
Mutual of America Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 8.2% in Q2 2026, buying an estimated $223K and bringing the position to 9,690 shares worth $2.92M. The position accounts for 0.03% of the portfolio, ranked #650.
Mutual of America Capital Management first reported a position in ALNY in Q2 2013 and has held it in 43 quarters since. The position peaked at $6.98M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Mutual of America Capital Management held 9,690 shares of Alnylam Pharmaceuticals worth $2.92M as of Q2 2026.
- Mutual of America Capital Management bought 738 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $223K.
- Alnylam Pharmaceuticals made up 0.03% of Mutual of America Capital Management's portfolio in Q2 2026, its #650 holding.
- Mutual of America Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- Mutual of America Capital Management's Alnylam Pharmaceuticals position peaked at $6.98M in Q3 2025.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.